AWM
MACK

Avior Wealth Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Avior Wealth Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2
Closed -$29 – 3917
2024
Q1 		$29 Buy
+2
New +$28 ﹤0.01% 3617

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Avior Wealth Management's MACK Position: Q2 2024 in Review

Avior Wealth Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 2 shares — an estimated $29 sold.

Avior Wealth Management first reported a position in MACK in Q1 2024 and held it in 1 quarter. The position peaked at $29 in Q1 2024. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • Avior Wealth Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 2 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $29.
  • Avior Wealth Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Merrimack Pharmaceuticals, Inc. position peaked at $29 in Q1 2024.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.